NewsBenzingaPAS-004 di Pasithea riduce i neurofibromi cutanei in tutti i 15 partecipanti valutabili, con una riduzione mediana massima del 41%, del 46% alle dosi previste per la fase 2, senza eventi avversi gravi correlati al trattamento PAS-004 di Pasithea riduce i neurofibromi cutanei in tutti i 15 partecipanti valutabili, con una riduzione mediana massima del 41%, del 46% alle dosi previste per la fase 2, senza eventi avversi gravi correlati al trattamento Benzinga 2026.11.13 07:21 (GMT+0) Open on Benzinga Other news Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead Binance to Remove 5 Spot Trading Pairs Including GAS/TRY and HBAR/BNB on November 20 Micron Technology (MU) Stock Is Trending After Hours: Here's Why
Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later
Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead